Cardiovascular Implantable Electronic Devices -> Monitoring & Outcomes: -> Monitoring & Follow-up D-PO05 - Poster Session V (ID 39) Poster

D-PO05-082 - Safety And Efficacy Of Watchman Device Implantation In Patients With Valvular Heart Disease A Multicenter Study (ID 539)


Background: Safety and Efficacy of Watchman device implantation in patients with valvular heart disease (VHD) has not been reported.
Objective: Our objective of study was to look whether watchman device would be as efficacious and safe in patient with valvular heart disease as in non valvular heart disease.
Methods: We report a multi-center observational study including all patients who underwent a Watchman device implantation across three centers in. Valvular heart disease (VHD) was defined as those who had moderate or severe mitral or aortic valve regurgitation, moderate or severe mitral stenosis, prior mitral or aortic valve repair or replacement.
Results: A total of 621 patients underwent Watchman device implantation, of which 60 patients (10%) had VHD and 561 patients (90%) had none. Peri-procedural minor or major complications occurred in 21 patients (3.0%), with no statistically significant difference in VHD and non-VHD group (2/60; 3.3%) vs 19/561; 3.4%), p=0.987). VHD patients were more likely to be men (p=0.002) and had a lower LVEF (p=0.002) when compared to non-VHD patients. Major bleeding events through 45 days and 1-year follow up were not different between VHD and non VHD group (p=0.806). There was no difference in the thromboembolic events or device related thrombosis between VHD and non-VHD at 45 day and 1-year follow-up.
Conclusion: Watchman device implantation is safe and efficacious in VHD patients despite discontinuing anticoagulants at 45 days.